Surgical oncologist Mr Myles Smith and colleagues recently had a review published into the current management of benign retroperitoneal tumours. This was featured in the European Journal of Surgical Oncology.
For the purpose of this review, benign retroperitoneal tumours (BRTs) were defined as, ‘any solid or cystic lesion arising in the retroperitoneal space and with no or remote potential of metastatic spread’. BRTs can present several diagnostic and therapeutic challenges because of their relative late presentation and anatomical location.
The review involved a literature search across publications that involved five different BRT biological subgroups including lipomatous tumours, smooth muscle tumours, peripheral nerve sheath tumours, myofibroblastic tumours, and others. What emerged was that there is a high chance of misdiagnosing a BRT with another pathology such as retroperitoneal sarcoma.
The review concluded that any suspected BRT should be referred to a specialised sarcoma centre. Here, a multidisciplinary sarcoma team can decide whether to offer surgery, nonsurgical treatment or a ‘watch-and-wait’ approach.
Moving forward, further collaborative and dedicated BRT research remains crucial in understanding this disease and to improve patient outcomes.
You can read the review here on ScienceDirect – https://authors.elsevier.com/c/1fSQA2gGSn-TNe